Working with the National Health Service (NHS)

At DAIICHI SANKYO UK, the National Health Service is our biggest stakeholder. That’s why we make it our business to understand the challenges faced by the four devolved nations. Variations in policy and funding are often determined by disease morbidity and mortality rates. In the south of England, for example, deaths arising from CVD are lower than in other UK regions*.

Regional guidance from the National Institute of Clinical Excellence (NICE), the Scottish Medicines Consortium and Scottish Intercollegiate Guidelines Network, and the All Wales Strategy Group has significant influence on prescribing and patient care.

Whilst we adapt our programmes to reflect the wider goals of the NHS, such as reducing the impact of CVD and diabetes**, we also tailor our service to meet the local needs of our customers. This collaborative approach between the NHS and industry, supported by the Darzi report***, enables pioneering treatments and models of care to be developed and delivered direct to patients.

Our customer focus

To meet the needs of the evolving NHS, commercial operations at DAIICHI SANKYO UK are structured into primary and secondary care business units. And we maintain our competitive edge by deploying our people and resources appropriately across the country, according to local or individual requirements.

We work with prescribing advisors, GPs, nurses, dispensing managers, practice managers and retail chemists in primary care – through to consultants, hospital doctors, nurses, business managers and pharmacists in secondary care.

With such a diverse range of customers, we train our people to the highest level to provide quality advice and information on all our products.

Highly-skilled medical liaison and medical services teams complement our sales and marketing specialists by providing essential clinical, scientific, pharmacovigilance and regulatory support to our UK customers.

^{* Scarborough P, Allender S, Peto V, and Rayner M (2008). Regional and social differences in Coronary Heart Disease 2008. British Heart Foundation: London
** CVD causes 208,000 deaths annually* and diabetes accounts for 5 per cent of NHS expenditure
*** High Quality Care for all, NHS Next stage review final report, Lord Darzi, DOH, June 2008}

If you experience any adverse effects whilst taking a DAIICHI SANKYO product, please report the event to:

Medical Services Department
DAIICHI SANKYO UK LTD
Chiltern Place
Chalfont Park, Gerrards Cross
SL9 0BG
01753 893600
Email: medinfo@daiichi-sankyo.co.uk

Medical personnel can obtain information on the reporting of adverse events on www.yellowcard.gov.uk.  

If you have a question about your medicine, or you are worried about your health, please speak to your doctor or pharmacist. Your doctor or pharmacist is in the best position to help you as they know your medical history.

If your doctor or pharmacist would like additional information on any DAIICHI SANKYO product, we will be happy to send the information directly to them on request.